XNAS · Healthcare · Biotechnology
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.08 | -0.08 | +0.00% | $563,000 | ➖ Inline | +2.92% | +3.11% | — |
| 2026-03-30 | Q4 2025 | -0.08 | -0.08 | +0.00% | $238,000 | ➖ Inline | -0.93% | -12.91% | -22.33% |
| 2025-11-13 |
| Q3 2025 |
| -0.08 |
| -0.08 |
| +0.00% |
| $266,000 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.08 | -0.08 | +0.00% | $422,000 | mixed | -3.23% | -27.95% | +3.23% |
| 2025-03-31 | Q4 2024 | -0.10 | -0.12 | -20.00% | $43,000 | ❌ Miss | -3.03% | -20.20% | -3.03% |
| 2024-11-13 | Q3 2024 | -0.12 | -0.10 | +16.67% | $0 | ✅ Beat | +0.00% | +9.17% | +17.43% |
| 2024-08-13 | Q2 2024 | -0.10 | -0.10 | +0.00% | $0 | ➖ Inline | -3.45% | -8.62% | -7.76% |
| 2024-05-10 | Q1 2024 | -0.16 | -0.07 | +56.25% | $0 | ✅ Beat | -2.76% | -5.52% | -28.97% |
Showing last 8 quarters.